<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5920">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01079832</url>
  </required_header>
  <id_info>
    <org_study_id>CASE13808</org_study_id>
    <secondary_id>NCI-2010-00285</secondary_id>
    <secondary_id>CASE13808</secondary_id>
    <nct_id>NCT01079832</nct_id>
  </id_info>
  <brief_title>Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies</brief_title>
  <official_title>A Prospective Evaluation of a Palliative Radio-Surgical Approach for the Treatment of Gynecologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Stereotactic radiosurgery can send x-rays directly to the tumor and cause less
      damage to normal tissue.

      PURPOSE: This clinical trial studies stereotactic radiosurgery using CyberKnife works in
      treating women with advanced or recurrent gynecological malignancies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. The primary goal of this study is to estimate the rate of grade 3 or higher acute
      toxicities observed during a 6 month period following CyberKnife radiosurgery for
      gynecologic cancers.

      II. To evaluate clinical response to radio-surgery for gynecologic tumors.

      III. To assess general and site specific quality of life (using SF-12, FACT-En, FACT-O,
      FACT-Cx or FACT-V) and to evaluate patient's level of pain.

      SECONDARY OBJECTIVES:

      I. As a secondary objective, toxicities during the 2 years following CyberKnife radiosurgery
      will also be described.

      OUTLINE:

      Patients undergo 3 fractions of CyberKnife stereotactic radiosurgery.

      After completion of study treatment, patients are followed at 1, 3, 6, 12, 18 and 24 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Acute Toxicity Rate</measure>
    <time_frame>at 6 months after treatment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The incidence of grade 3 or 4 possible SBRT-related non-hematological toxicities observed during a 6 month period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free Survival</measure>
    <time_frame>completion of study at 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Median disease free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Overall Survival</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Length of time patients survived at study end.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>After completion of study treatment, patients are followed at 1, 3, 6, 12, 18 and 24 months.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Response Rate</measure>
    <time_frame>at 6 months from study entry</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of patients with a clinical response following RECIST (Response Evaluation Criteria in Solid Tumors) Criteria: Confirmed complete response(CR), Stable disease (SD), partial response (PR), or without progressive disease (PD).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Ovarian Sarcoma</condition>
  <condition>Ovarian Stromal Cancer</condition>
  <condition>Recurrent Cervical Cancer</condition>
  <condition>Recurrent Endometrial Carcinoma</condition>
  <condition>Recurrent Ovarian Epithelial Cancer</condition>
  <condition>Recurrent Ovarian Germ Cell Tumor</condition>
  <condition>Recurrent Uterine Sarcoma</condition>
  <condition>Recurrent Vaginal Cancer</condition>
  <condition>Recurrent Vulvar Cancer</condition>
  <condition>Stage III Cervical Cancer</condition>
  <condition>Stage III Endometrial Carcinoma</condition>
  <condition>Stage III Ovarian Epithelial Cancer</condition>
  <condition>Stage III Ovarian Germ Cell Tumor</condition>
  <condition>Stage III Uterine Sarcoma</condition>
  <condition>Stage III Vaginal Cancer</condition>
  <condition>Stage III Vulvar Cancer</condition>
  <condition>Stage IV Endometrial Carcinoma</condition>
  <condition>Stage IV Ovarian Epithelial Cancer</condition>
  <condition>Stage IV Ovarian Germ Cell Tumor</condition>
  <condition>Stage IV Uterine Sarcoma</condition>
  <condition>Stage IV Vulvar Cancer</condition>
  <condition>Stage IVA Cervical Cancer</condition>
  <condition>Stage IVA Vaginal Cancer</condition>
  <condition>Stage IVB Cervical Cancer</condition>
  <condition>Stage IVB Vaginal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I: CyberKnife Radiosurgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo 3 fractions of CyberKnife stereotactic radiosurgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>stereotactic radiosurgery</intervention_name>
    <description>Radiation will be delivered in 3 fractions. The dose level will range between 500 to 800cGy per fraction at the discretion of the treating radiation oncologist</description>
    <arm_group_label>Arm I: CyberKnife Radiosurgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I: CyberKnife Radiosurgery</arm_group_label>
    <other_name>quality of life assessment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion

          -  Pathologically proven gynecologic malignancy

          -  No prior cryosurgery or radiofrequency ablation, in target lesion

          -  Patient is able to give and sign study specific informed consent

          -  Measurable disease, according to RECIST criteria

          -  Laboratory parameters and appropriate clearance from anesthesia based on other
             medical co-morbidities for placement of fiducials; these would include CBC, basic
             metabolic panel, BUN, and creatinine

          -  &gt;= 4 weeks from previous treatment (chemotherapy or radiation) of malignancy

          -  ECOG performance status of 0-3 as this procedure is minimally invasive and considered
             palliative in these patients

        Exclusion

          -  Any patient with active connective tissue disease such as lupus or dermatomyositis is
             excluded

          -  Any patient with active Crohn's disease or active ulcerative colitis is excluded

          -  Major medical or psychiatric illness, which would prevent completion of treatment or
             interfere with follow-up is excluded
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert DeBernardo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 27, 2013</lastchanged_date>
  <firstreceived_date>March 2, 2010</firstreceived_date>
  <firstreceived_results_date>July 19, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Germinoma</mesh_term>
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Vaginal Neoplasms</mesh_term>
    <mesh_term>Vulvar Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between July 24,2009 and September 7, 2011, 50 patients were recruited from University Hospitals in Cleveland Ohio.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm I: CyberKnife Radiosurgery</title>
          <description>Patients undergo 3 fractions of CyberKnife stereotactic radiosurgery.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I: CyberKnife Radiosurgery</title>
          <description>Patients undergo 3 fractions of CyberKnife stereotactic radiosurgery.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="50"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="66" lower_limit="27" upper_limit="82"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="50"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Not Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="48"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="45"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>More than one race</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="50"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Acute Toxicity Rate</title>
        <description>The incidence of grade 3 or 4 possible SBRT-related non-hematological toxicities observed during a 6 month period.</description>
        <time_frame>at 6 months after treatment</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I: CyberKnife Radiosurgery</title>
            <description>Patients undergo 3 fractions of CyberKnife stereotactic radiosurgery.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Acute Toxicity Rate</title>
            <description>The incidence of grade 3 or 4 possible SBRT-related non-hematological toxicities observed during a 6 month period.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease-free Survival</title>
        <description>Median disease free survival</description>
        <time_frame>completion of study at 24 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I: CyberKnife Radiosurgery</title>
            <description>Patients undergo 3 fractions of CyberKnife stereotactic radiosurgery.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Disease-free Survival</title>
            <description>Median disease free survival</description>
            <units>months</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="7.8" lower_limit="4" upper_limit="11.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Overall Survival</title>
        <description>Length of time patients survived at study end.</description>
        <time_frame>24 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I: CyberKnife Radiosurgery</title>
            <description>Patients undergo 3 fractions of CyberKnife stereotactic radiosurgery.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Median Overall Survival</title>
            <description>Length of time patients survived at study end.</description>
            <units>months</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20.2" lower_limit="10" upper_limit="29.5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life</title>
        <time_frame>After completion of study treatment, patients are followed at 1, 3, 6, 12, 18 and 24 months.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Participant surveys were unreliably returned to investigators, making this analysis not meaningful.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I: CyberKnife Radiosurgery</title>
            <description>Patients undergo 3 fractions of CyberKnife stereotactic radiosurgery.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Quality of Life</title>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Response Rate</title>
        <description>Percentage of patients with a clinical response following RECIST (Response Evaluation Criteria in Solid Tumors) Criteria: Confirmed complete response(CR), Stable disease (SD), partial response (PR), or without progressive disease (PD).</description>
        <time_frame>at 6 months from study entry</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I: CyberKnife Radiosurgery</title>
            <description>Patients undergo 3 fractions of CyberKnife stereotactic radiosurgery.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Clinical Response Rate</title>
            <description>Percentage of patients with a clinical response following RECIST (Response Evaluation Criteria in Solid Tumors) Criteria: Confirmed complete response(CR), Stable disease (SD), partial response (PR), or without progressive disease (PD).</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="68" lower_limit="53" upper_limit="80"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected while patients were receiving treatment and during 6 months of follow up.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm I: CyberKnife Radiosurgery</title>
          <description>Patients undergo 3 fractions of CyberKnife stereotactic radiosurgery.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death not associated with CTCAE term - Disease progression NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Bilirubin (hyperbilirubinemia)</sub_title>
                <description>Additional adverse events associated with this hospitalization were:
Grade 1 INR (International Normalized Ratio of prothrombin time) Grade 2 Liver dysfunction/failure (clinical)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <description>Confusion - Brain metastasis</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Pain - Abdomen NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>&quot;Fatigue (asthenia, lethargy, malaise)&quot;</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Edema: limb</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - Back</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Pain - Chest wall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Charles Kunos</name_or_title>
      <organization>Case Comprehensive Cancer Center</organization>
      <phone>330-375-4485</phone>
      <email>kunosc@summahealth.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
